Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × HER2-positive Breast Cancer × Paclitaxel × Clear all

Phase

Phase 3 3 Phase 2 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 54 Carcinoma, Non-Small-Cell Lung 41 Ovarian Neoplasms 27 Stomach Neoplasms 22 Neoplasms 19 Lung Neoplasms 18 Neoplasm Metastasis 17 Squamous Cell Carcinoma of Head and Neck 15 Fallopian Tube Neoplasms 14 Triple Negative Breast Neoplasms 13 Esophageal Neoplasms 11 Carcinoma, Ovarian Epithelial 9 Esophageal Squamous Cell Carcinoma 8 Colorectal Neoplasms 8 Melanoma 7 Head and Neck Neoplasms 7 Uterine Cervical Neoplasms 6 Pancreatic Neoplasms 6 Endometrial Neoplasms 6 Carcinoma, Renal Cell 6 Small Cell Lung Carcinoma 5 Prostatic Neoplasms 5 Adenocarcinoma of Lung 5 Urinary Bladder Neoplasms 4 Testicular Neoplasms 4 Testicular Germ Cell Tumor 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Carcinoma, Transitional Cell 4 Carcinoma, Squamous Cell 4 Carcinoma 4

Interventions

Trastuzumab 3 pertuzumab 2 Docetaxel 2 palbociclib 1 Protons 1 Paclitaxel 1 Letrozole 1 Fulvestrant 1 Fluorodeoxyglucose F18 1 Enfuvirtide 1 Doxorubicin 1 Cyclophosphamide 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02379585 2018-04-24

STEFNE

Western Regional Medical Center

Phase 1/2 Terminated

8 enrolled 1 chart

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡